Suptavumab

Drug Profile

Suptavumab

Alternative Names: REGN-2222; SAR-438584

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 14 Aug 2017 Discontinued - Phase-III for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Australia, New Zealand, USA, Bulgaria, Denmark, Finland, Hungary, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, South Africa, Turkey, Canada, Chile, Ukraine, Panama, Germany (IM)
  • 05 May 2017 Regeneron Pharmaceuticals completes enrolment in a phase III trial for Respiratory syncytial virus infections in USA Bulgaria, Denmark, Finland, Hungary, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, Australia, New Zealand, South Africa, Turkey, Canada, Chile, Ukraine, Panama, and Germany
  • 01 Sep 2016 Regeneron Pharmaceuticals completes a phase I trial in Healthy volunteers in USA (IM) (NCT02828397)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top